Information and dialogue

Developing a new medicine is a long and laborious process that is also associated with very high costs. A key part of the working process that leads to approval is thus that the Swedish Medical Products Agency, in dialogue with the pharmaceutical industry, at an early stage states the facts it needs to review in order to grant approval.

This information cuts development times, which benefits the company in the form of lower development costs, and health and medical care in earlier access to new drugs.


 

 
 
 

Swedish Medical Products Agency, P.O. Box 26, SE-751 03 Uppsala, SWEDEN | +46 18 17 46 00 | registrator@lakemedelsverket.se | Contact information